SOMATROGON
somatrogon 24 mg/1.2 mL injection, 1.2 mL pen device
SOMATROGON (13119L)
13119L
Manner of administration:Injection
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Initial treatment
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Recommencement of treatment
Restriction
Indication: Short stature associated with biochemical growth hormone deficiency
Treatment phase: Recommencement of treatment as a reclassified patient
Restriction
Indication: Short stature and slow growth
Treatment phase: Initial treatment
Restriction
Indication: Short stature and slow growth
Treatment phase: Recommencement of treatment
Restriction
Indication: Short stature and slow growth
Treatment phase: Recommencement of treatment as a reclassified patient
Quantities & Cost
| Max qty packs | Max qty units | # of repeats | DPMQ | Max safety net | General Patient Charge |
|---|---|---|---|---|---|
| Max qty packs: 1 | Max qty units: 1 | # of repeats: 1 | DPMQ: $383.80 | Max safety net: $25.00 | General Patient Charge: $25.00 |
| Available brands | |||||
| Ngenla | |||||